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Abstract: A respiratory syncytial virus (RSV) is the major cause of respiratory tract infection in
children under 5 years. However, RSV infection in the European Region of the World Health
Organization has not been systematically reviewed. The aim was to determine the prevalence and
factors associated with RSV in children under 5 years of age in European regions. A systematic
review and meta-analysis was performed. CINAHL, Medline, LILACS, ProQuest, SciELO, and
Scopus databases were consulted for studies published in the last 5 years, following Preferred
Reporting Items for Systematic Reviews and Meta-analysis guidelines. The search equation was
“respiratory syncytial virus AND (newborn OR infant OR child) AND (prevalence OR risk factors)”.
Studies reporting the prevalence of RSV were eligible for inclusion in the meta-analysis. A total
of 20 articles were included. The meta-analytic prevalence estimation of RSV, with a sample of
n = 16,115 children, was 46% (95% CI 34–59%). The main risk factors were age, male gender,
winter season, and environmental factors such as cold temperatures, higher relative humidity, high
concentrations of benzene, exposure to tobacco, and living in urban areas. Robust age-specific
estimates of RSV infection in healthy children should be promoted in order to determine the optimal
age for immunization. In addition, it is necessary to analyse in greater depth the potentially predictive
factors of RSV infection, to be included in prevention strategies.
Keywords: respiratory syncytial virus; risk factors; prevalence; children; epidemiology; meta-
analysis
1. Introduction
Respiratory syncytial virus (RSV) is a single-stranded RNA virus that belongs to the
Paramyxoviridae family, affecting respiratory epithelial cells and presenting two subtypes,
RSV A (the most severe form of presentation) and RSV B [1].
It is one of the main causes of acute lower respiratory tract infection (ALRI), partic-
ularly in children under one year of age [2]. Worldwide, it is estimated that there are
33 million cases of ALRI per year associated with RSV in children under 5 years of age [3]
of which 3.2 million cases require hospitalization [4]. In addition, RSV is one of the main
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causes of mortality with about 60 thousand deaths per year throughout the world in
children under 5 years of age [5].
RSV is characterized by being seasonal, whose infection rate peaks in the cold season in
temperate climates [6]. Primary infection from 6 months to 2 years is usually symptomatic,
with around 40% of infections presenting bronchiolitis and pneumonia. The incubation
period of the infection ranges from 3 to 5 days, and the clinical presentation of RSV can vary
according to age, with the most common symptoms being rhinorrhoea, nasal congestion,
cough, fever or respiratory distress [7]. Up to 40% of infants progress to ALRI with coughing
and wheezing, which range in severity from mild to moderate illness to life-threatening
respiratory failure [8]. In addition, the consequences can be negative, especially in children
with underlying diseases (prematurity, lung disease, congenital heart disease, congenital
or acquired immunodeficiency, or Down syndrome) [9–11].
Currently, the drug of choice as prophylaxis to prevent RSV infection is palivizumab,
being recommended for high-risk population [12]. However, the high rate of hospitalization
and mortality has produced a growing interest in new vaccines and therapies against RSV,
in order to include a larger target population such as infants, pregnant women, or the
elderly population [13,14]. In the past decade, 10 vaccines and 11 therapeutic agents in
active clinical trials have been developed, noting that maternal vaccination is particularly
relevant [13]. New treatments have also been developed such as Ribavirin, although not
routinely recommended in light of limited evidence of benefit [15]. Nevertheless, the
treatment and prophylaxis options are still limited.
In 2015, the World Health Organization (WHO) indicated a high priority on establish-
ing global RSV disease surveillance systems, as well as robust age-specific estimations in
order to determine the optimal age for immunization [16]. However, data on the preva-
lence of RSV and the burden of disease in healthy children are scarce, as most studies are
conducted only in high-risk groups [17–19].
Specifically, in Europe, there are few studies on RSV infection. Some studies have
investigated the seasonality and geography of RSV in European countries [20]. However,
to date, there is no systematic review that evaluates the prevalence and risk factors of RSV
in healthy children in the WHO European Region. Therefore, and in order to obtain a better
understanding of the severity of RSV infection, the objective of this systematic review and
meta-analysis is to analyse the prevalence and risk factors of RSV infection in children
under 5 years of age.
2. Materials and Methods
A systematic review was performed following PRISMA statement (Preferred Report-
ing Items for Systematic Reviews and Meta-analyses) [21].
2.1. Data Sources and Search Strategy
CINAHL, Medline, LILACS, ProQuest, SciELO and Scopus databases were consulted.
The search was done in December 2020, using MeSH descriptors and with the following
search equation: “respiratory syncytial virus AND (newborn OR infant OR child) AND
(prevalence OR risk factors)”.
2.2. Study Selection Process
Two authors independently analysed the title and abstract of the articles found,
eliminating duplicate studies. Subsequently, the full-texts were reviewed, evaluating them
according to inclusion criteria. In case of disagreement, a third author was consulted.
2.3. Inclusion and Exclusion Criteria
The inclusion criteria were the following: (1) countries included in the WHO European
Region; (2) published in English, French, Spanish, Portuguese, and Italian; (3) published in
the last 5 years; (4) children under 5 years of age; (5) gestational age greater than 37 weeks;
(6) diagnosis of acute respiratory tract infection (respiratory infection, pneumonia, or
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bronchiolitis); (7) RSV diagnosis confirmed by laboratory tests; (8) prevalence measurement
showing RSV infection positive rate outcome data or providing enough information to
calculate the effect size (number of RSV infected patients and total number of patients);
and (9) RSV-associated factors.
Articles that did not meet the following criteria were excluded: (1) without a clear
diagnosis of RSV, (2) studies that included a high-risk population (with a diagnosis of
chronic lung disease, bronchopulmonary dysplasia, cystic fibrosis, or premature infants),
(3) with prior prophylaxis (palivizumab or other prevention strategies for RSV infection),
and (4) case definition that was not clearly defined.
We did not include studies published before 2015 because seasonality could change
and our objective was to report on current global seasonality. There were no restrictions on
the healthcare setting or definition of RSV infection.
2.4. Data Extraction
Two authors extracted data from all included studies using a data coding form. A
third author checked the data for disagreement. The following variables were obtained
for each of the articles: (1) author, year of publication, and country; (2) design and study
period; (3) age; (4) diagnostic procedure used; (5) sample; (6) place of detection of the case;
(7) prevalence; and (8) risk factors.
To assess the reliability of the data coding by the researchers, the intraclass correlation
coefficient was calculated as 0.98 (minimum = 0.97; maximum = 1). Cohen’s Kappa
coefficient used for categorical variables was 0.97 (minimum = 0.96; maximum = 1).
2.5. Quality Evaluation and Risk Bias
In order to assess the quality of the studies included in the review, the levels of
evidence and grades of recommendation of the Oxford Center for Evidence-based Medicine
(OCEBM) were followed [22], as well as the STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology) guide [23].
2.6. Data Analysis
A random effects meta-analysis was performed to calculate the prevalence of RSV and
the corresponding confidence interval. The software used was StatsDirect (StatsDirect Ltd.,
Cambridge, UK), presenting the results grouped in a forest plot.
Analysis of heterogeneity was performed by measuring I2. There was significant
heterogeneity if the I2 values were greater than 50% [24]. Publication bias was assessed
using Egger’s linear regression test and also a sensitivity analysis was performed.
3. Results
The initial search strategy identified 2823 references. After reading the title and
abstract, 1153 were eliminated. After reading the full text, a total of 177 articles were
eliminated. The selection of articles is reflected in Figure 1.
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Figure 1. Flow diagram of the selection process. 
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Bulgaria (n = 3). Regarding methodological quality, all studies had an adequate level of 
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3.1. Characteristics of Included Studies
The sample consisted of a total of n = 16,115 children. Most of the studies were cohort
studies (75%), followed by cross-sectional studies (20%) and cases and controls (5%). Most
of the studies were conducted in Italy (n = 6), followed by the Netherlands (n = 3) and
Bulgaria (n = 3). Regarding methodological quality, all studies had an adequate level of
quality. The evaluation and characteristics of the studies are represented in Table 1.
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3.2. Risk Factor (Age)
The hospitalization rate presents an inversely proportional relationship to age, reach-
ing a maximum in the first months of life [29,36]. For some, in the first 6 months, there
is a greater RSV infection [32,34], although other authors find that the frequency of RSV-
positives increases after 5 months of age compared to those from 0 to 4 months [30].
However, for other authors, the highest number of cases is between the first and third year
of life [35,42]. See Table 2.
Table 2. Main risk factors associated with RSV infection.
Author, (year) Risk Factors
Atay et al. [26], 2020
Male gender (OR 1.73, 95% CI 1.0–5.7%, p = 0.302)
Crowded household population (OR 1.73, 95% CI 1.0–5.7%, p = 0.046)
Heating stoves (OR 0.31, 95% CI 0.1–0.98%, p = 0.025)
Urban cities (p < 0.001)
Exposure to smoking (p = 0.001)
Peak February
Cangiano et al. [29], 2016
Younger (p < 0.001)
Peak December–February
Maternal smoke during pregnancy (p = 0.036)
Esposito et al. [30], 2016
Age (OR 6.3, 95% CI 1.4–33.9%, p = 0.02)
Age ≥ 5 months old (children 5–8 months old and 9–16 months old vs.
children
0–4 months old: p = 0.03 and p = 0.003, respectively)
Attended day care (p = 0.001)
Birth date (OR 2.7, 95% CI 1.1–6.7%, p = 0.03)
Male gender (OR 2.3, 95% CI 1.0–5.7%, p = 0.06)
Gökçe et al. [32], 2017 Peak January–MarchYounger (<6 months)
Karppinen et al. [33], 2016 Male (OR 1.06, 95% CI 0.57–1.99%, p = 0.85)Socioeconomic status (OR 0.78, 95% CI 0.39–1.56%, p = 0.48)
Korsun et al. [34], 2019
Youngest age group: <6 months (50%), followed by 6–11 months (38.5%)
Of the RSV-positive children 58.5% were under 2 years of age: 61% were
boys and 39% were girls (p = 0.5773)
Kutsaya et al. [35], 2016 RSV seroprevalence increased from 37% at age 1 year to 68% at age 2 years,and to 86% at age 3 years
Midulla et al. [36], 2019
Younger (p < 0.0001)
Lower body weight at admission (p = 0.005)
Born in winter
Nenna et al. [37], 2017
The number of RSV-positive infants correlated negatively with cold
temperature (r = −0.46, p < 0.001), and positively with higher relative
humidity (r = 0.36, p < 0.001)
Peak December–February
Petrarca et al. [38], 2018 No relation to exposure to smoke, breastfeeding, birth weight and sex
Ramos-Fernández et al. [39], 2017 Male (OR 4.27, 95% CI 1.14–15.93%, p = 0.03)Low birth weight (<3rd percentile) (OR 5.53, 95% CI 0.93–32.97%, p = 0.06)
Resch et al. [40], 2019 No relation to smoking during pregnancyPeak January
Toivonen et al. [42], 2020
Of all RSV infections, 10% occurred before 3 months of age, 16% at 3–5
months of age, 32% at 6–11 months of age, and 42% at 12–24 months of age
Peak February–May
Van de Steen et al. [43], 2016 Duration of hospitalization (p < 0.001)
3.3. Risk Factor (Gender and Weight at Birth)
Regarding gender, there is a relationship between male gender and RSV infection,
presenting a higher percentage of infection [30,33,34,39], although other authors do not
find any relationship [38].
Low birth weight is also considered a risk factor [36] and more specifically if it is
below the third percentile [39], although other authors find no relationship [38,40].
3.4. Risk Factor (Seasonality)
The seasonal distribution of RSV reaches its maximum peak during the winter season,
for some during the months of January–February [26,40], December–February [29,37,38],
January–March [32], and February–May [42].
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3.5. Environmental Risk Factors
A negative correlation is found between cold temperatures and the number of RSV
positive children as well as the number of hospitalizations [37]; and a positive correlation
if there is a higher relative humidity [37]. The spikes of contagion by RSV are also related
to certain atmospheric pollutants such as benzene [37].
The environmental home conditions, such as the use of heating with stoves, are related
to the number of cases of RSV infection, finding that these children present more serious
episodes. In addition, exposure to tobacco is also considered a risk factor [26,29,40].
3.6. Another Risk Factors
In relation to the place of residence, there is an increase in the number of RSV hospi-
talizations in children living in urban areas and in the crowded household population [26].
Those children who attend kindergarten [30] have a higher rate of RSV infection. Moreover,
the risk increases the longer the length of hospital stay [43].
3.7. Meta-Analysis Prevalence Estimation
The sample of the meta-analysis was n = 16,115 children. The meta-analytical es-
timation of RSV was 46% (95% CI 34–59%). The I2 value was 99.4% indicating a high
heterogeneity. Egger test did not show publication bias and no study was removed after
the sensitivity analysis. The forest plot is shown in Figure 2.
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4. Discussion
The prevalence of RSV infection in children from WHO European countries was
46% (95% CI 34–59%). This percentage is similar to that of other continents such as Latin
America, with an RSV prevalence of 41.5% (95% CI 32–51.4%) [45]. Other authors find
a global positive rate of RSV infection lower than that of this study, as is the case in
Africa with a prevalence of 14.6% (95% CI 13–16.4%) [46] or China with 16% (95% CI
12.9–19.6%) [47]. Even studies carried out in European countries such as France find a
lower prevalence of positive RSV of 12–18% [48] and in the US the percentages of RSV
infection in healthy children are only 1.8% [49].
Regarding age, we found that RSV infection was detected more frequently in children
up to 3 years of age. These results are similar to those of other studies that confirm a
significantly higher rate in children under 3 years of age (19.5%) compared to children over
3 years of age (5.6%) [47]. Even multicenter studies find that in children under 6 months
the prevalence is 50% and in children under 2 years of age 88%, a fact that corroborates
the high burden of RSV in children < 2 years, especially in infants < 6 months [50,51]. The
younger the age, the greater the risk of RSV infection, as corroborated by several authors,
indicating a greater risk especially in children between 3 to 5 months [48,52,53], although
other studies point out that RSV-associated hospitalizations reach their maximum peak in
children under 3 months [54]. Other authors suggest a higher percentage of infection in
children 0 to 12 months of age [45,54–58].
Gender influences RSV infection, boys have a higher risk of severe RSV infection
compared to girls [48,59]. Some studies that have investigated these differences in greater
depth indicate an infection ratio of two boys for every girl, the difference in the sex ratio
being the highest in the first months of life [59].
Episodes of infection usually occur between November and March, with a peak in
January–February [51]. Even some studies when analysing the percentage of RSV infection
and its relationship with the month of birth, find a low prevalence for children born in
April of 5.7%, being higher in children born in November, of 49.6% [60].
Climatic factors also contribute to promoting RSV infection. Like our results, many
studies have highlighted that colder temperatures during the months with the highest
RSV prevalence are associated with a greater probability of hospitalization for RSV [51,57].
Furthermore, the positivity of RSV is also higher in environmental conditions of high
relative humidity, high atmospheric pressure and even wind speed [51,61].
Other authors, as in this study, consider the importance of exposure to tobacco smoke
as a risk factor for RSV infection, aggravating the severity of bronchiolitis or the risk
of other acute lower respiratory tract infections [62], although others do not find this
association [51,63].
RSV positivity is higher in children with characteristics such as low socioeconomic
status and the length of the children’s hospital stay also has a negative influence [51]. In
this review, we did not find a relationship between maternal aspects and RSV infection,
while other studies indicate a short duration of breastfeeding as a risk factor as well as
being born by spontaneous vaginal delivery [51].
The high rate of RSV infection and its negative consequences for the health of children
makes it necessary to analyse the existing prevalence, as well as the associated risk factors
to prioritize and early identify children at high risk of developing infection associated with
RSV [64]. However, most of the research is focused on analysing RSV-associated infection
without providing data on its classification according to age.
Hospital admissions for respiratory infections due to RSV remain a significant health
problem among young children. However, underreporting, misclassification, and lack
of national guidelines regarding RSV diagnostic testing indicate that statistics are rarely
sufficient to estimate the incidence or prevalence of RSV-associated disease, which implies
more studies in order to know real data [64]. Furthermore, few studies have been conducted
to assess the burden of RSV infection in healthy children. A global report of the monthly
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activity of these viruses is needed to develop public health strategies and programs for
their control.
Further efforts are needed to find new strategies to reduce the RSV. Thus, developing
measures in order to reduce children’s exposure to indoor and outdoor pollution and iden-
tifying additional environmental factors, would contribute to reducing RSV hospitalization
and morbidity and mortality.
Limitations
First, the number of studies is low because not all studies reported the prevalence
of RSV or its risk factors. Furthermore, many studies contemplated different respiratory
diseases in the global population without analysing the different age groups. Second, the
analysis of risk factors has been performed individually, lacking multivariate analysis.
Finally, although the inclusion criteria were established to find studies with similar
populations, there was high heterogeneity between the studies. It can be explained by the
diversity of countries, where the health-seeking behaviour of populations is likely to vary
depending on different cultural contexts.
5. Conclusions
To our knowledge, this is the first meta-analysis to address the prevalence of RSV
infection and associated factors in children under 5 years of age in the WHO European
Regions. A 46% prevalence of RSV was observed. Among the main risk factors are age,
male gender, winter season, and environmental factors such as cold temperatures, higher
relative humidity, high concentrations of benzene, exposure to tobacco, and living in
urban areas. All of them are potentially predictive factors to prevent the development of
RSV infection and, therefore, should be taken into account when establishing prevention
strategies. RSV infection in children, as the most vulnerable group, deserves more research,
particularly at promoting the provision of a vaccine for this population group.
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